Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Renovorx Inc
(NQ:
RNXT
)
1.020
-0.010 (-0.97%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Renovorx Inc
< Previous
1
2
3
Next >
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer
September 28, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer
September 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022
September 07, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Second Quarter 2022 Financial Results
August 15, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Appoints James Ahlers as Chief Financial Officer
July 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Launches “The RenovoRx Story” Video Series
July 13, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022
June 09, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022
June 02, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform’s Potential Utility for the Treatment of Bile Duct Cancer
May 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022
May 18, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports First Quarter 2022 Financial Results
May 16, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Reports Full Year 2021 Financial Results
March 30, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial
February 22, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET
February 03, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer
January 19, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022
From
RenovoRx, Inc.
Via
Business Wire
RenovoRx Announces Third Quarter 2021 Financial Results
November 15, 2021
From
RenovoRx
Via
Business Wire
RenovoRx Announces Presentation of Final Data from RR2 Observational Registry Study at 2021 Pancreas Club Annual Meeting
November 11, 2021
From
RenovoRx, Inc.
Via
Business Wire
Presentation During New Advances in the Management of Pancreatic Cancer Course Highlights Intra-Arterial Chemotherapy as a Potential Innovative Treatment for Pancreatic Cancer
November 09, 2021
From
RenovoRx, Inc.
Via
Business Wire
InvestorNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Closes $16.7M IPO
September 22, 2021
Via
Investor Brand Network
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.